Results 71 to 80 of about 2,004 (157)

Complement mediated thrombotic microangiopathy after liver transplantation in combination with a novel C6 variant of uncertain significance

Frontiers in Immunology
Thrombotic microangiopathies (TMAs) encompass a spectrum of severe pathological conditions mostly characterized by hemolytic anemia, microvascular thrombosis with organ failure, and thrombocytopenia.
Nicola Sariye Pollmann, Lisa Hauptmann, Martin Busch, Lukas Pollmann, Andrea Tannapfel, Oliver Rohland, Aladdin Ali Deeb, Falk Rauchfuß, Utz Settmacher, Felix Dondorf   +9 more
doaj   +1 more source

Complement C5 Inhibition and Short-Term Cardiovascular Outcomes After Acute Limb Ischemia: A Real-World Cohort Study

International Journal of Translational Medicine
Background: Acute limb ischemia (ALI) is a vascular emergency characterized by abrupt limb hypoperfusion, ischemia–reperfusion injury, and a high risk of thromboinflammatory and organ complications.
Carl Vahldieck, Benedikt Fels
doaj   +1 more source

Successful haploidentical hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with severe pancytopenia developed after long‐term aplastic anemia treatment

Clinical Case Reports
Key Clinical Message Haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide is an alternative treatment for aplastic anemia–paroxysmal nocturnal hemoglobinuria (PNH) syndrome with poor prognostic factors ...
Kazuki Sakurai, Kei Saito, Shunsuke Hatta, Yuna Katsuoka, Kuniaki Meguro, Hisayuki Yokoyama, Toru Izumi   +6 more
doaj   +1 more source

Atypical Hemolytic Uremic Syndrome Associated With Malignant Hypertension Presenting With Pulmonary-Renal Syndrome-like Symptoms

Kidney Medicine
Both atypical hemolytic uremic syndrome (aHUS) and malignant hypertension (MHT) are causes of thrombotic microangiopathy (TMA), and their coexistence has been reported. We describe a 22-year-old man who exhibited severe hypertension, pulmonary hemorrhage,
Hiroyuki Okawa, Yukihiro Wada, Noritoshi Kato, Mayuko Hanyuda, Ryota Uchitubo, Tetsuya Abe, Kazuhiro Takeuchi, Yasushi Nagaba, Shoichi Maruyama, Yasuo Takeuchi   +9 more
doaj   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life [PDF]

Kidney International Reports, 2021
Christophe Legendre, Rebecca-Sberro-Soussan, Julien Zuber   +2 more
openaire   +3 more sources

Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study

Health and Quality of Life Outcomes
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder. Symptoms such as fatigue can have a substantial impact on patients’ physical activity levels, sleep, quality of life, and work productivity. Ravulizumab treatment can
Elizabeth A. Griffiths, Jae S. Min, Wei-Nchih Lee, Jeffrey C. Yu, Yogesh Patel, Karl-Johan Myren, David Dingli   +6 more
doaj   +1 more source

Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies

Journal of Comparative Effectiveness Research
What is this summary about? Neuromyelitis optica spectrum disorder (NMOSD for short) is a rare autoimmune health condition, meaning that the body’s natural defense system (the immune system) attacks the body’s own tissues.
Alfredo Damasceno, Mariano Marrodan
doaj   +1 more source

Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy. [PDF]

Blood Adv
Höchsmann B, Gerber GF, Leopold W, Patel BJ, Gavriilaki E, Hefter A, Kalhammer U, Opitz S, Marx-Hoffmann A, Knight DB, Brodsky RA, Marvaki A, Lalayanni C, Körper S, Babushok DV, Schrezenmeier H.   +15 more
europepmc   +1 more source